�ʘ���

�ʘ��� (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to �ʘ��� in the fast-growing VTE segment.

“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, Chair and Chief Executive Officer, �ʘ���. “We look forward to welcoming the talented Inari team to �ʘ��� and working together to improve outcomes for patients worldwide.”